Search company, investor...

Otsuka Health Solutions


Acquired | Acquired

About Otsuka Health Solutions

Otsuka Health Solutions is a division of Otsuka Pharmaceutical Europe that utilizes medical data to gain valuable insights into mental health. Its data analysis assists decisions on resource allocation, supports patient flow, and identifies people at risk of using crisis services. On April 27th, 2021, Otsuka Health Solutions was acquired by Holmusk. The terms of the transaction were not disclosed.

Headquarters Location

Gallions Framewood Road

Wexham Springs, England, SL3 6PJ,

United Kingdom

+44 (0)7826 913269

Missing: Otsuka Health Solutions's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Otsuka Health Solutions's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Otsuka Health Solutions

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Otsuka Health Solutions is included in 2 Expert Collections, including Mental Health Tech.


Mental Health Tech

1,285 items

This collection includes companies applying technology to problems of emotional, psychological, and social well-being. Examples include companies working in areas such as substance abuse, eating disorders, stress reduction, depression, PTSD, and anxiety.


Digital Health

10,347 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

Latest Otsuka Health Solutions News

EC approval for Otsuka’s treatment for lupus nephritis

Sep 22, 2022

The European Commission (EC) has approved Otsuka Pharmaceutical Europe Ltd’s Lupkynis®▼ (voclosporin) in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN). Voclosporin is the first and only oral treatment approved in Europe for the treatment of active […]

Otsuka Health Solutions Frequently Asked Questions (FAQ)

  • Where is Otsuka Health Solutions's headquarters?

    Otsuka Health Solutions's headquarters is located at Gallions, Wexham Springs.

  • What is Otsuka Health Solutions's latest funding round?

    Otsuka Health Solutions's latest funding round is Acquired.

  • Who are the investors of Otsuka Health Solutions?

    Investors of Otsuka Health Solutions include Holmusk and NHS Innovation Accelerator.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.